ARA-290 — Peptide Protocol Wiki reference
patient_educationexpert_opinion · status: needs_provider_reviewDetails
Summary (generated — provider review required)
ARA-290 (Cibinetide): Neuroprotective Peptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides? Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About ARA-290 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides ARA-290 Brain & Neuroprotection Anti-Inflammatory phase2 ARA-290 Also known as: Cibinetide, Helix B Surface Peptide Research compiled by Peptide Protocol Wiki 📅 Updated February 8, 2026 Citations Verified TL;DR ARA-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the tissue-protective domain of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR) to provide neuroprotective and anti-inflammatory effects without stimulating red blood cell production.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (8) · phenotypes (0)
evidence_reference, safety_reference, dosing_reference, mechanism, contraindication_reference
Findings (54) · awaiting review (34)
safety · pending
Comprehensive human safety data may be limited.
safety · pending
Consult the detailed side effects profile for full information.
regulatory · pending
FDA Orphan Drug designation for sarcoidosis; not approved for clini
mechanism · pending
cal use Regulations vary by country and may change.
regulatory · pending
FDA Fast Track for chronic low back pain.
outcome · pending
The improvements persisted through a 28-day post-treatment observation period.
safety · pending
ARA-290 (Cibinetide): Neuroprotective Peptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?
dosing · pending
Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About ARA-290 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides ARA-290 Brain & Neuroprotection Anti-Inflammatory phase2 ARA-290 Also known as: Cibinetide, Helix B Surface Peptide Research compiled by Peptide Protocol Wiki 📅 Updated February 8, 2026 Citations Verified TL;DR ARA-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the tissue-protective domain of erythropoietin (EPO).
mechanism · pending
It selectively activates the innate repair receptor (IRR) to provide neuroprotective and anti-inflammatory effects without stimulating red blood cell production.
regulatory · pending
Browse all neuroprotective peptides → Table of Contents 📌 TL;DR • Selective neuroprotective and tissue-protective properties • Does not stimulate erythropoiesis (no cardiovascular risk from increased hematocrit) • FDA Orphan Drug designation for sarcoidosis • Clinical trial data in human patients with neuropathic conditions Community-Repor
safety · pending
ted Side Effects Anecdotal ?
dosing · pending
📋 Protocol Quick-Reference Neuropathic pain relief and small nerve fiber regeneration 💉 Dosing Amount 4 mg Frequency Once daily Duration 28 days 💊 Administration Route SC Schedule Once daily Timing Any time of day; no meal timing requirements ✓ Rotate injection sites 📅 Cycle Duration 28 days Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Store lyophilized peptide at -20C.
mechanism · pending
Despite a short plasma half-life (minutes), ARA-290 triggers sustained biological effects when concentrations exceed the low nanomolar receptor affinity threshold.
contraindication · pending
⚗️ Suggested Bloodwork ( 6 tests) CBC with differential When: Baseline Why: Baseline; ARA-290 is derived from EPO structure but should not affect erythropoiesis CMP When: Baseline Why: Liver and kidney function baseline HbA1c When: Baseline Why: Baseline glycemic control (studied in type 2 diabetes neuropathy) Lipid panel When: Baseline Why: Baseline; some improvement in lipids observed in clinical trials Corneal confocal microscopy (if available) When: Baseline Why: Baseline nerve fiber density measurement CBC When: 2 weeks Why: Verify no erythropoietic stimulation (ARA-290 should not increase RBC) 💡 Key Considerations → Despite this, daily dosing is used because the innate repair receptor requires daily activation for nerve regeneration → Contraindication: Avoid in active cancer or myeloproliferative disorders due to EPO-derived mechanism; though ARA-290 is sp
regulatory · pending
Regulatory Status # ARA-290 has received FDA Orphan Drug designation for the treatment of sarcoidosis, recognizing the unmet medical need in this patient p
outcome · pending
Restore access No thanks, continue reading Related Reading Peptide EPO erythropoietin neuroprotective hormone Peptide Cerebrolysin neuroprotective peptide mixture Peptide Ara 290 peptide How ARA-290 works at the cellular level Overview of ARA-290 benefits and applications Scientific Details Molecular Formula C52H91N17O21 Molecular Weight 1257.35 Da CAS Number 1208243-50-8 Sequence QEQLERALNSS What is ARA-290?
outcome · pending
This selective activity profile makes ARA-290 suitable for therapeutic applications where tissue protection is desired without the cardiovascular risks associated with EPO-induced increases in hematocrit.
mechanism · pending
The peptide was developed based on the discovery by Michael Brines and Anthony Cerami that EPO signals through two distinct receptor systems: the classical EPO receptor homodimer (responsible for erythropoiesis) and t
mechanism · pending
he innate repair receptor (IRR), a heteromer of the EPO receptor and the beta common receptor (CD131), which mediates tissue protection and repair.
mechanism · pending
Mechanism of Action # ARA-290 selectively activates the innate repair receptor (IRR), a heteromeric complex composed of the erythropoietin receptor (EPOR) and the beta common receptor (CD131/betacR).
mechanism · pending
This receptor complex is expressed on multiple cell types including neurons, Schwann cells, endothelial cells, and immune cells, particularly at sites of tissue injury and inflammation.
mechanism · pending
Innate Repair Receptor Signaling # Upon binding to the IRR, ARA-290 activates downstream signaling pathways including JAK2-STAT5, PI3K-Akt, and NF-kB modulation.
mechanism · pending
These pathways collectively mediate anti-inflammatory effects, anti-apoptotic signaling, promotion of nerve fiber regeneration, and modulation of immune cell activity.
outcome · pending
This shift reduces the production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) while promoting the release of anti-inflammatory mediators and growth factors that support tissue repair.
mechanism · pending
The mechanism involves both direct neuroprotective effects on neurons and indirect effects through modulation of the local inflammatory environment.
dosing · pending
Sarcoidosis-Associated Neuropathy # A 2012 randomized, double-blind, placebo-controlled pilot study in 22 sarcoidosis patients with small fiber neuropathy (SFN) showed that ARA-290 (2 mg IV, three times weekly for 4 weeks) significantly improved SFN screening scores compared to placebo, with no safety concerns identified.
dosing · pending
A follow-up 2013 study demonstrated that 28 days of daily subcutaneous ARA-290 improved neuropathic symptoms and increased corneal nerve fiber density in sarcoidosis patients.
dosing · pending
Diabetic Neuropathy # A clinical study in patients with type 2 diabetes showed that daily subcutaneous ARA-290 (4 mg) for 28 days improved hemoglobin A1c, lipid profiles, neuropathic symptoms, and corneal nerve fiber density.
regulatory · pending
Important Considerations # ARA-290 is an investigational compound that has not yet received regulatory approval for any indication.
safety · pending
While clinical trial data are encouraging, the compound is still in Phase 2 development, and larger Phase 3 trials would be needed to confirm efficacy and establish a comprehensive safety profile.
dosing · pending
The compound's short plasma half-life has implications for dosing frequency and route of administration.
safety · pending
Key Research Findings # Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study , published in Molecular Medicine (Heij L et al., 2012; PMID: 23168581): First randomized, double-blind, placebo-controlled trial of ARA-290 in sarcoidosis patients with small fiber neuropathy, showing significant improvement in neuropathic symptoms with no safety concerns.
dosing · pending
Significant improvement in SFN screening score at week 4 vs placebo No safety concerns identified ARA-290 2 mg IV three times weekly for 4 weeks was well tolerated ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density , published in Molecular Medicine (Dahan A et al., 2013; PMID: 24136731): Follow-up study demonstrating that 28 days of daily subcutaneous ARA-290 improved neuropathic symptoms and increased corneal nerve fiber density in sarcoidosis patients with documented small nerve fiber loss.
outcome · pending
Improved neuropathi
mechanism · pending
Pain Management Brain & Neuroprotection Cebranopadol Cebranopadol (GRT-6005): first-in-class dual NOP/opioid receptor agonist for pain.
dosing · pending
c symptom scores Increased corneal nerve fiber density (objective measure of nerve regeneration) Effects observed in patients with documented small nerve fiber loss ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes , published in Molecular Medicine (Brines M et al., 2015; PMID: 25387363): Clinical study showing that daily subcutaneous ARA-290 for 28 days improved hemoglobin A1c, lipid profiles, and neuropathic symptoms in patients with type 2 diabetes, with increased corneal nerve fiber density.
dosing · pending
Improvement in hemoglobin A1c Improved lipid profiles Significant improvement in neuropathic symptoms Related Reading # ARA-290 research studies and evidence ARA-290 dosing protocols ARA-290 side effects profile BPC-157 research guide Semax research guide Stay current on ARA-290 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.
outcome · pending
What are the benefits of ARA-290?
outcome · pending
Research suggests the following potential benefits of ARA-290: Selective neuroprotective and tissue-protective properties.
outcome · pending
Does not stimulate erythropoiesis (no cardiovascular risk from increased hematocrit).
Processing
Processed into 11 searchable sections.